Antiproliferative effects of GnRH agonists: Prospects and problems for cancer therapy

Neuroendocrinology

Volumn 88, Issue 2, 2008, Pages 67-79

  White, Colin D ^a   Stewart, Alan J ^a   Lu, Zhi Liang ^a   Millar, Robert P ^a   Morgan, Kevin ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cancer therapy; Cell proliferation; GnRH agonists; GnRH receptors; Reproduction

Indexed keywords

COMPLEMENTARY DNA; GONADORELIN AGONIST; GONADORELIN RECEPTOR; GUANOSINE TRIPHOSPHATASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHOLIPASE C; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SEX HORMONE;

CANCER CELL; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; ENDOMETRIUM CANCER; GENE EXPRESSION; HUMAN; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CANCER; REPRODUCTION; REVIEW;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; GENE EXPRESSION REGULATION, DEVELOPMENTAL; GONADOTROPIN-RELEASING HORMONE; HUMANS; MODELS, BIOLOGICAL; NEOPLASMS, HORMONE-DEPENDENT; RECEPTORS, LHRH; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION;

EID: 50649125221     PISSN: 00283835     EISSN: None     Source Type: Journal    
DOI: 10.1159/000119093     Document Type: Review

References (127)

1. Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR: Gonadotropin-releasing hormone receptors. Endocr Rev 2004;25:235-275.
2. Morgan K, Conklin D, Pawson AJ, Sellar R, Ott TR, Millar RP: A transcriptionally active human type II gonadotropin-releasing hormone receptor gene homolog overlaps two genes in the antisense orientation on chromosome 1q12. Endocrinology 2003;144:423-436.
3. Morgan K, Sellar R, Pawson AJ, Lu ZL, Millar RP: Bovine and ovine gonadotropin-releasing hormone (GnRH)-II ligand precursors and type II GnRH receptor genes are functionally inactivated. Endocrinology 2006;147:5041-5051.
4. Gault PM, Morgan K, Pawson AJ, Millar RP, Lincoln GA: Sheep exhibit novel variations in the organization of the mammalian type II gonadotropin-releasing hormone receptor gene. Endocrinology 2004;145:2362-2374.
5. Engel JB, Schally AV: Drug insight: clinical use of agonists and antagonists of luteinizing hormone-releasing hormone. Nat Clin Pract Endocrinol Metab 2007;3:157-167.
6. Vincze B, Palyi I, Daubner D, Kremmer T, Szamel I, Bodrogi I, Sugar J, Seprodi J, Mezo I, Teplan I, Eckhardt S: Influence of luteinizing hormone-releasing hormone agonists on human mammary carcinoma cell lines and their xenografts. J Steroid Biochem Mol Biol 1991;38:119-126.
7. Yano T, Korkut E, Pinski J, Szepeshazi K, Milovanovic S, Groot K, Clarke R, Comaru-Schally AM, Schally AV: Inhibition of growth of MCF-7 MIII human breast carcinoma in nude mice by treatment with agonists or antagonists of LH-RH. Breast Cancer Res Treat 1992;21:35-45.
8. Wells A, Souto JC, Solava J, Kassis J, Bailey KJ, Turner T: Luteinizing hormone-releasing hormone agonist limits DU-145 prostate cancer growth by attenuating epidermal growth factor receptor signaling. Clin Cancer Res 2002;8:1251-1257.
9. Seeburg PH, Adelman JP: Characterization of cDNA for precursor of human luteinizing hormone-releasing hormone. Nature 1984;311:666-668.
10. White RB, Eisen JA, Kasten TL, Fernald RD: Second gene for gonadotropin-releasing hormone in humans. Proc Natl Acad Sci USA 1998;95:305-309.
11. Kakar SS, Musgrove LC, Devor DC, Sellers JC, Neill JD: Cloning, sequencing, and expression of human gonadotropin-releasing hormone (GnRH) receptor. Biochem Biophys Res Commun 1992;189:289-295.
12. Minaretzis D, Jakubowski M, Mortola JF, Pavlou SN: Gonadotropin-releasing hormone receptor gene expression in human ovary and granulosa-lutein cells. J Clin Endocrinol Metab 1995;80:430-434.
13. Azad N, Uddin S, La Paglia N, Kirsteins L, Emanuele NV, Lawrence AM, Kelley MR: Luteinizing hormone-releasing hormone (LHRH) in rat prostate: characterization of LHRH peptide, messenger ribonucleic acid expression, and molecular processing of LHRH in intact and castrated male rats. Endocrinology 1993;133:1252-1257.
14. Kang SK, Choi KC, Cheng KW, Nathwani PS, Auersperg N, Leung PC: Role of gonadotropin-releasing hormone as an autocrine growth factor in human ovarian surface epithelium. Endocrinology 2000;141:72-80.
15. Tieva A, Stattin P, Wikstrom P, Bergh A, Damber JE: Gonadotropin- releasing hormone receptor expression in the human prostate. Prostate 2001;47:276-284.
16. Fan NC, Peng C, Krisinger J, Leung PC: The human gonadotropin-releasing hormone receptor gene: complete structure including multiple promoters, transcription initiation sites, and polyadenylation signals. Mol Cell Endocrinol 1995;107:1-8.
17. Duval DL, Nelson SE, Clay CM: The tripartite basal enhancer of the gonadotropin-releasing hormone (GnRH) receptor gene promoter regulates cell-specific expression through a novel GnRH receptor activating sequence. Mol Endocrinol 1997;11:1814-1821.
18. Granger A, Ngô-Muller V, Bleux C, Guigon C, Pincas H, Magre S, Daegelen D, Tixier-Vidal A, Counis R, Laverrière JN: The promoter of the rat gonadotropin-releasing hormone receptor gene directs the expression of the human placental alkaline phosphatase reporter gene in gonadotrope cells in the anterior pituitary gland as well as in multiple extrapituitary tissues. Endocrinology 2004;145:983-993.
19. Kawamura K, Fukuda J, Kumagai J, Shimizu Y, Kodama H, Nakamura A, Tanaka T: Gonadotropin-releasing hormone I analog acts as an antiapoptotic factor in mouse blastocysts. Endocrinology 2005;146:4105-4116.
20. Spergel DJ, Kruth U, Hanley DF, Sprengel R, Seeburg PH: GABA- and glutamate-activated channels in green fluorescent protein-tagged gonadotropin-releasing hormone neurons in transgenic mice. J Neurosci 1999;19:2037-2050.
21. Suter KJ, Song WJ, Sampson TL, Wuarin JP, Saunders JT, Dudek FE, Moenter SM: Genetic targeting of green fluorescent protein to gonadotropin-releasing hormone neurons: characterization of whole-cell electrophysiological properties and morphology. Endocrinology 2000;141:412-419.
22. Todman MG, Han SK, Herbison AE: Profiling neurotransmitter receptor expression in mouse gonadotropin-releasing hormone neurons using green fluorescent protein-promoter transgenics and microarrays. Neuroscience 2005;132:703-712.
23. Treier M, Gleiberman AS, O'Connell SM, Szeto DP, McMahon JA, McMahon AP, Rosenfeld MG: Multistep signaling requirements for pituitary organogenesis in vivo. Genes Dev 1998;12:1691-1704.
24. Tanaka M, Lyons GE, Izumo S: Expression of the Nkx3.1 homobox gene during pre- and postnatal development. Mech Dev 1999;85:179-182.
25. Gu G, Yuan J, Wills M, Kasper S: Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res 2007;67:4807-4815.
26. Ruf F, Fink MY, Sealfon SC: Structure of the GnRH receptor-stimulated signaling network: insights from genomics. Front Neuroendocrinol 2003;24:181-199.
27. Yuen T, Wurmbach E, Ebersole BJ, Ruf F, Pfeffer RL, Sealfon SC: Coupling of GnRH concentration and the GnRH receptor-activated gene program. Mol Endocrinol 2002;16:1145-1153.
28. Bahk JY, Hyun JS, Lee H, Kim MO, Cho GJ, Lee BH, Choi WS: Expression of gonadotropin-releasing hormone (GnRH) and GnRH receptor mRNA in prostate cancer cells and effect of GnRH on the proliferation of prostate cancer cells. Urol Res 1998;26:259-264.
29. Dondi D, Limonta P, Moretti RM, Marelli MM, Garattini E, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone (LHRH) agonists on human androgen-independent prostate cancer cell line DU 145: evidence for an autocrine-inhibitory LHRH loop. Cancer Res 1994;54:4091-4095.
30. Halmos G, Arencibia JM, Schally AV, Davis R, Bostwick DG: High incidence of receptors for luteinizing hormone-releasing hormone (LHRH) and LHRH receptor gene expression in human prostate cancers. J Urol 2000;163:623-629.
31. Kakar SS, Grizzle WE, Neill JD: The nucleotide sequences of human GnRH receptors in breast and ovarian tumors are identical with that found in pituitary. Mol Cell Endocrinol 1994;106:145-149.
32. Kottler ML, Starzec A, Carre MC, Lagarde JP, Martin A, Counis R: The genes for gonadotropin-releasing hormone and its receptor are expressed in human breast with fibrocystic disease and cancer. Int J Cancer 1997;71:595-599.
33. Mangia A, Tommasi S, Reshkin SJ, Simone G, Stea B, Schittulli F, Paradiso A: Gonadotropin-releasing hormone receptor expression in primary breast cancer: comparison of immunohistochemical, radioligand and Western blot analyses. Oncol Rep 2002;9:1127-1132.
34. Chatzaki E, Bax CM, Eidne KA, Anderson L, Grudzinskas JG, Gallagher CJ: The expression of gonadotropin-releasing hormone and its receptor in endometrial cancer, and its relevance as an autocrine growth factor. Cancer Res 1996;56:2059-2065.
35. Nagai N, Oshita T, Mukai K, Shiroyama Y, Shigemasa K, Ohama K: GnRH agonist inhibits human telomerase reverse transcriptase mRNA expression in endometrial cancer cells. Int J Mol Med 2002;10:593-597.
36. Yin H, Cheng KW, Hwa H-L, Peng C, Auersperg N, Leung PCK: Expression of the messenger RNA for gonadotropin-releasing hormone and its receptor in human cancer cell lines. Life Sci 1998;62:2015-2023.
37. Imai A, Ohno T, Iida K, Fuseya T, Furui T, Tamaya T: Gonadotropin- releasing hormone receptor in gynecologic tumors. Frequent expression in adenocarcinoma histologic types. Cancer 1994;74:2555-2561.
38. Moretti RM, Montagnani Marelli M, Van Groeninghen JC, Limonta P: Locally expressed LHRH receptors mediate the oncostatic and antimetastatic activity of LHRH agonists on melanoma cells. J Clin Endocrinol Metab 2002;87:3791-3797.
39. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Westphal G, Halmos G, Engel JB: Human malignant melanomas express receptors for luteinizing hormone-releasing hormone allowing targeted therapy with cytotoxic luteinizing hormone-releasing hormone analogue. Cancer Res 2005;65:5857-5863.
40. Keller G, Schally AV, Gaiser T, Nagy A, Baker B, Halmos G, Engel JB: Receptors for luteinizing hormone-releasing hormone (LHRH) expressed in human non-Hodgkin's lymphomas can be targeted for therapy with the cytotoxic LHRH analogue AN-207. Eur J Cancer 2005;41:2196-2202.
41. Jungwirth A, Schally AV, Halmos G, Groot K, Szepeshazi K, Pinski J, Armatis P: Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist cetrorelix, somatostatin analog RC-160 and bombesin antagonist RC-3940-II. Cancer 1998;82:909-917.
42. Karande AA, Rajeshwari K, Schol DJ, Hilgers JHM: Establishment of immunological probes to study human gonadotropin-releasing hormone receptors. Mol Cell Endocrinol 1995;114:51-56.
43. Limonta P, Moretti RM, Marelli MM, Dondi D, Parenti M, Motta M: The luteinizing hormone-releasing hormone receptor in human prostate cancer cells: messenger ribonucleic acid expression, molecular size, and signal transduction pathway. Endocrinology 1999;140:5250-5256.
44. Limonta P, Dondi D, Moretti RM, Maggi R, Motta M: Antiproliferative effects of luteinizing hormone-releasing hormone agonists on the human prostatic cancer cell line LNCaP. J Clin Endocrinol Metab 1992;75:207-212.
45. Emons G, Pahwa GS, Ortmann O, Knuppen R, Oberheuser F, Schulz K-D: LHRH-receptors and LHRH-agonist treatment in ovarian cancer: an overview. J Steroid Biochem Mol Biol 1990;37:1003-1006.
46. Emons G, Schally AV: The use of luteinizing hormone-releasing hormone agonists and antagonists in gynaecological cancers. Hum Reprod 1994;9:1364-1379.
47. Segal-Abramson T, Kitroser H, Levy J, Schally AV, Sharoni Y: Direct effects of luteinizing hormone-releasing hormone agonists and antagonists on MCF-7 mammary cancer cells. Proc Natl Acad Sci USA 1992;89:2336-2339.
48. Volker P, Grundker C, Schmidt O, Schulz KD, Emons G: Expression of receptors for luteinizing hormone-releasing hormone in human ovarian and endometrial cancers: frequency, autoregulation, and correlation with direct antiproliferative activity of luteinizing hormone-releasing hormone analogues. Am J Obstet Gynecol 2002;186:171-179.
49. Halmos G, Schally AV, Kahan Z: Down-regulation and change in subcellular distribution of receptors for luteinizing hormone-releasing hormone in OV-1063 human epithelial ovarian cancers during therapy with LHRH antagonist cetrorelix. Int J Oncol 2000;17:367-373.
50. Baumann KH, Kiesel L, Kaufmann M, Bastert G, Runnebaum B: Characterization of binding sites for a GnRH-agonist (buserelin) in human breast cancer biopsies and their distribution in relation to tumor parameters. Breast Cancer Res Treat 1993;25:37-46.
51. Irmer G, Bürger C, Müller R, Ortmann O, Peter U, Kakar SS, Neill JD, Schulz K-D, Emons G: Expression of the messenger RNAs for luteinizing hormone-releasing hormone (LHRH) and its receptor in human ovarian epithelial carcinoma. Cancer Res 1995;55:817-822.
52. Schally AV, Comaru-Schally AM, Nagy A, Kovacs M, Szepeshazi K, Plonowski A, Varga JL, Halmos G: Hypothalamic hormones and cancer. Front Neuroendocrinol 2001;22:248-291.
53. Dondi D, Moretti RM, Montagnani Marelli M, Pratesi G, Polizzi D, Milani M, Motta M, Limonta P: Growth-inhibitory effects of luteinizing hormone-releasing hormone (LHRH) agonists on xenografts of the DU 145 human androgen-independent prostate cancer cell line in nude mice. Int J Cancer 1998;76:506-511.
54. Grundker C, Gunthert AR, Westphalen S, Emons G: Biology of the gonadotropin-releasing hormone system in gynecological cancers. Eur J Endocrinol 2002;146:1-14.
55. Miller WR, Scott WN, Morris R, Fraser HM, Sharpe RM: Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985;313:231-233.
56. Yano T, Pinski J, Radulovic S, Schally AV: Inhibition of human epithelial ovarian cancer cell growth in vitro by agonistic and antagonistic analogues of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1994;91:1701-1705.
57. Tolis G, Ackman D, Stellos A, Mehta A, Labrie F, Fazekas AT, Comaru-Schally AM, Schally AV: Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. Proc Natl Acad Sci USA 1982;79:1658-1662.
58. Carr BR, Marshburn PB, Weatherall PT, Bradshaw KD, Breslau NA, Byrd W, Roark M, Steinkampf MP: An evaluation of the effect of gonadotropin-releasing hormone analogs and medroxyprogesterone acetate on uterine leiomyomata volume by magnetic resonance imaging: a prospective, randomized, double-blind, placebo-controlled, crossover trial. J Clin Endocrinol Metab 1993;76:1217-1223.
59. Jeyarajah AR, Gallagher CJ, Blake PR, Oram DH, Dowsett M, Fisher C, Oliver RT: Long-term follow-up of gonadotrophin-releasing hormone analog treatment for recurrent endometrial cancer. Gynecol Oncol 1996;63:47-52.
60. Klijn JG, de Jong FH: Treatment with a luteinising hormone-releasing hormone analogue (buserelin) in premenopausal patients with metastatic breast cancer. Lancet 1982;1:1213-1216.
61. Celio L, Martinetti A, Ferrari L, Buzzoni R, Mariani L, Miceli R, Seregni E, Procopio G, Cassata A, Bombardieri E, Bajetta E: Premenopausal breast cancer patients treated with a gonadotropin-releasing hormone analog alone or in combination with an aromatase inhibitor: a comparative endocrine study. Anticancer Res 1999;19:2261-2268.
62. Hofstra LS, Mourits MJ, de Vries EG, Mulder NH, Willemse PH: Combined treatment with goserelin and tamoxifen in patients with advanced chemotherapy resistant ovarian cancer. Anticancer Res 1999;19:3627-3630.
63. Gnanapragasam VJ, Darby S, Khan MM, Lock WG, Robson CN, Leung HY: Evidence that prostate gonadotropin-releasing hormone receptors mediate an anti-tumourigenic response to analogue therapy in hormone refractory prostate cancer. J Pathol 2005;206:205-213.
64. Limonta P, Moretti RM, Marelli MM, Motta M: The biology of gonadotropin hormone-releasing hormone: role in the control of tumor growth and progression in humans. Front Neuroendocrinol 2003;24:279-295.
65. i- coupling state of the type I GnRH receptor. Cancer Res 2004;64:7533-7544.
66. Emons G, Gründker C, Günthert AR, Westphalen S, Kavanagh J, Verschraegen C: GnRH antagonists in the treatment of gynecological and breast cancers. Endocr Relat Cancer 2003;10:291-299.
67. q/11 proteins. J Biol Chem 2000;275:9193-9200.
68. Dobkin-Bekman M, Naidich M, Pawson AJ, Millar RP, Seger R, Naor Z: Activation of mitogen-activated protein kinase (MAPK) by GnRH is cell-context dependent. Mol Cell Endocrinol 2006;252:184-190.
69. Liu J, Yang G, Thompson-Lanza JA, Glassman A, Hayes K, Patterson A, Marquez RT, Auersperg N, Yu Y, Hahn WC, Mills GB, Bast RC: A genetically defined model for human ovarian cancer. Cancer Res 2004;64:1655-1663.
70. Lawson DA, Xin L, Lukacs RU, Cheng D, Witte ON: Isolation and functional characterization of murine prostate stem cells. Proc Natl Acad Sci USA 2007;104:181-186.
71. Franklin J, Hislop J, Flynn A, McArdle CA: Signalling and anti-proliferative effects mediated by gonadotrophin-releasing hormone receptors after expression in prostate cancer cells using recombinant adenovirus. J Endocrinol 2003;176:275-284.
72. Finch AR, Green L, Hislop JN, Kelly E, McArdle CA: Signaling and antiproliferative effects of type I and II gonadotropin-releasing hormone receptors in breast cancer cells. J Clin Endocrinol Metab 2004;89:1823-1832.
73. Brothers SP, Janovick JA, Conn PM: Calnexin regulated gonadotropin-releasing hormone receptor plasma membrane expression. J Mol Endocrinol 2006;37:479-488.
74. Janovick JA, Maya-Nunez G, Conn PM: Rescue of hypogonadotropic hypogonadism-causing and manufactured GnRH receptor mutants by a specific protein-folding template: misrouted proteins as a novel disease etiology and therapeutic target. J Clin Endocrinol Metab 2002;87:3255-3262.
75. Maudsley S, Naor Z, Bonfil D, Davidson L, Karali D, Pawson AJ, Larder R, Pope C, Nelson N, Millar RP, Brown P: Proline-rich tyrosine kinase 2 mediates gonadotropin-releasing hormone signaling to a specific extracellularly regulated kinase-sensitive transcriptional locus in the luteinizing hormone β-subunit gene. Mol Endocrinol 2007;21:1216-1233.
76. Wing MR, Houston D, Kelley GG, Der CJ, Siderovski DP, Harden TK: Activation of phospholipase Cε by heterotrimeric G protein βγ-subunits. J Biol Chem 2001;276:48257-48261.
77. 2 links the binding of Gβγ to activation of the catalytic core. J Biol Chem 2000;275:7466-7469.
78. q directly activates p63RhoGEF and Trio via a conserved extension of the Dbl homology-associated pleckstrin homology domain. J Biol Chem 2007;282:29201-29210.
79. Masumoto N, Tasaka K, Kasahara K, Miyake A, Tanizawa O: Purification of gonadotropes and intracellular free calcium oscillation. Effects of gonadotropin-releasing hormone and interleukin 6. J Biol Chem 1991;266:6485-6488.
80. Leong DA, Thorner MO: A potential code of luteinizing hormone-releasing hormone-induced calcium ion responses in the regulation of luteinizing hormone secretion among individual gonadotropes. J Biol Chem 1991;266:9016-9022.
81. 2+ oscillations. Proc Natl Acad Sci USA 1994;91:9750-9754.
82. Orrenius S, Zhivotovsky B, Nicotera P: Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol 2003;4:552-565.
83. 2+-sensor proteins: from Alzheimer's disease to cancer. Trends Pharmacol Sci 2005;26:345-351.
84. Hilfiker S: Neuronal calcium sensor-1: a multifunctional regulator of secretion. Biochem Soc Trans 2003;31:828-832.
85. 2+-binding proteins in the retina: structure, function, and the etiology of human visual diseases. Bioessays 2000;22:337-350.
86. Maeda A, Ohguro H, Maeda T, Wada I, Sato N, Kuroki Y, Nakagawa T: Aberrant expression of photoreceptor-specific calcium-binding protein (recoverin) in cancer cell lines. Cancer Res 2000;60:1914-1920.
87. Maeda A, Maeda T, Ohguro H, Palczewski K, Sato N: Vaccination with recoverin, a cancer-associated retinopathy antigen, induces autoimmune retinal dysfunction and tumor cell regression in mice. Eur J Immunol 2002;32:2300-2307.
88. Mahloogi H, González-Guerrico AM, Lopez De Cicco R, Bassi DE, Goodrow T, Braunewell KH, Klein-Szanto AJ: Overexpression of the calcium sensor visinin-like protein-1 leads to a cAMP-mediated decrease of in vivo and in vitro growth and invasiveness of squamous cell carcinoma cells. Cancer Res 2003;63:4997-5004.
89. Gonzalez Guerrico AM, Jaffer ZM, Page RE, Braunewell KH, Chernoff J, Klein-Szanto AJ: Visinin-like protein-1 is a potent inhibitor of cell adhesion and migration in squamous carcinoma cells. Oncogene 2005;24:2307-2316.
90. Rokhlin OW, Taghiyev AF, Bayer KU, Bumcrot D, Koteliansk VE, Glover RA, Cohen MB: Calcium/calmodulin-dependent kinase II plays an important role in prostate cancer cell survival. Cancer Biol Ther 2007;6:732-742.
91. 2+/calmodulin and ERK1/2 signaling pathways. Cell Mol Life Sci 2007;64:1437-1448.
92. 2- Chimaerin is a novel target for diacylglycerol: binding properties and changes in subcellular localization mediated by ligand binding to its C1 domain. Proc Natl Acad Sci USA 1999;96:11854-11859.
93. 2-chimerin. J Biol Chem 2005;280:24363-24370.
94. Mellor H, Parker PJ: The extended protein kinase C superfamily. Biochem J 1998;332:281-292.
95. Pearson G, Robinson F, Beers Gibson TB, Xu BE, Karandikar M, Berman K, Cobb MH: Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocr Rev 2001;22:153-183.
96. Chen Z, Gibson TB, Robinson F, Silvestro L, Pearson G, Xu BE, Wright A, Vanderbilt C, Cobb MH: MAP kinases. Chem Rev 2001;101:2449-2476.
97. Lewis TS, Shapiro PS, Ahn NG: Signal transduction through MAP kinase cascades. Adv Cancer Res 1998;74:49-139.
98. Cobb MH, Goldsmith EJ: How MAP kinases are regulated. J Biol Chem 1995;270:14843-14846.
99. Su B, Karin M: Mitogen-activated protein kinase cascades and regulation of gene expression. Curr Opin Immunol 1996;8:402-411.
100. Koike K, Fujii T, Nakamura AM, Yokoyama G, Yamana H, Kuwano M, Shirouzu K: Activation of protein kinase Cδ induces growth arrest in NPA thyroid cancer cells through extracellular signal-regulated kinase mitogen-activated protein kinase. Thyroid 2006;16:333-341.
101. Goulet AC, Chigbrow M, Frisk P, Nelson MA: Selenomethionine induces sustained ERK phosphorylation leading to cell-cycle arrest in human colon cancer cells. Carcinogenesis 2005;26:109-117.
102. Traverse S, Gomez N, Paterson H, Marshall C, Cohen P: Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem J 1992;288:351-355.
103. Marshall CJ: Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 1995;80:179-185.
104. Pumiglia KM, Decker SJ: Cell cycle arrest mediated by the MEK/mitogen-activated protein kinase pathway. Proc Natl Acad Sci USA 1997;94:448-452.
105. Song Y, Wong C, Chang DD: Overexpression of wild-type RhoA produces growth arrest by disrupting actin cytoskeleton and microtubules. J Cell Biochem 2000;80:229-240.
106. Davidson L, Pawson AJ, Millar RP, Maudsley S: Cytoskeletal reorganization dependence of signaling by the gonadotropin-releasing hormone receptor. J Biol Chem 2004;279:1980-1993.
107. Felton-Edkins ZA, Fairley JA, Graham EL, Johnston IM, White RJ, Scott PH: The mitogen-activated protein (MAP) kinase ERK induces tRNA synthesis by phosphorylating TFIIIB. EMBO J 2003;22:2422-2432.
108. Glading A, Uberall F, Keyse SM, Lauffenburger DA, Wells A: Membrane proximal ERK signaling is required for M-calpain activation downstream of epidermal growth factor receptor signaling. J Biol Chem 2001;276:23341-23348.
109. Barco A, Bailey CH, Kandel ER: Common molecular mechanisms in explicit and implicit memory. J Neurochem 2006;97:1520-1533.
110. Eisinger DA, Schulz R: Extracellular signal-regulated kinase/mitogen-activated protein kinases block internalization of δ-opioid receptors. J Pharmacol Exp Ther 2004;309:776-785.
111. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ: Integration of MAP kinase signal transduction pathways at the serum response element. Science 1995;269:403-407.
112. Cohen-Armon M: PARP-1 activation in the ERK signaling pathway. Trends Pharmacol Sci 2007;28:556-560.
113. Janknecht R: Analysis of the ERK-stimulated ETS transcription factor ER81. Mol Cell Biol 1996;16:1550-1556.
114. Okazaki K, Sagata N: The Mos/MAP kinase pathway stabilizes c-Fos by phosphorylation and augments its transforming activity in NIH3T3 cells. EMBO J 1995;14:5048-5059.
115. Gilmore TD: The Rel/NF-κB signal transduction pathway: introduction. Oncogene 1999;18:6842-6844.
116. Nguyen DH, Catling AD, Webb DJ, Sankovic M, Walker LA, Somlyo AV, Weber MJ, Gonias SL: Myosin light chain kinase functions downstream of Ras/ERK to promote migration of urokinase-type plasminogen activator-stimulated cells in an integrin-selective manner. J Cell Biol 1999;146:149-164.
117. Reffas S, Schlegel W: Compartment-specific regulation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) mitogen-activated protein kinases (MAPKs) by ERK-dependent and non-ERK-dependent inductions of MAPK phosphatase (MKP)-3 and MKP-1 in differentiating P19 cells. Biochem J 2000;352:701-708.
118. Vicent GP, Ballaré C, Nacht AS, Clausell J, Subtil- Rodríguez A, Quiles I, Jordan A, Beato M: Induction of progesterone target genes requires activation of ERK and MSK kinases and phosphorylation of histone H3. Mol Cell 2006;24:367-381.
119. Pintus G, Tadolini B, Posadino AM, Sanna B, Debidda M, Bennardini F, Sava G, Ventura C: Inhibition of the MEK/ERK signaling pathway by the novel antimetastatic agent NAMI-A down regulates c-myc gene expression and endothelial cell proliferation. Eur J Biochem 2002;269:5861-5870.
120. Persons DL, Yazlovitskaya EM, Pelling JC: Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000;275:35778-35785.
121. Frödin M, Gammeltoft S: Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol Cell Endocrinol 1999;151:65-77.
122. Mikkola I, Bruun JA, Bjorkoy G, Holm T, Johansen T: Phosphorylation of the transactivation domain of Pax6 by extracellular signal-regulated kinase and p38 mitogen-activated protein kinase. J Biol Chem 1999;274:15115-15126.
123. O'Hagan RC, Tozer RG, Symons M, McCormick F, Hassell JA: The activity of the Ets transcription factor PEA3 is regulated by two distinct MAPK cascades. Oncogene 1996;13:1323-1333.
124. Dobrenski AF, Zeft AS, Wellstein A, Riegel AT: DNA binding of the transcription factor PO-B is regulated during differentiation of HL-60 cells. Cell Growth Differ 1993;4:647-656.
125. Wang Y, Prywes R: Activation of the c-fos enhancer by the ERK MAP kinase pathway through two sequence elements: the c-fos AP-1 and p62TCF sites. Oncogene 2000;19:1379-1385.
126. Dong C, Waters SB, Holt KH, Pessin JE: SOS phosphorylation and disassociation of the Grb2-SOS complex by the ERK and JNK signaling pathways. J Biol Chem 1996;271:6328-6332.
127. Stefanovsky VY, Pelletier G, Hannan R, Gagnon-Kugler T, Rothblum LI, Moss T: An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. Mol Cell 2001;8:1063-1073.